FULC · Fulcrum Therapeutics, Inc. · Investor Relations
$3.70
-0.02 (-0.54%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$283.83M
Shares
76.30M
Volume · Oct 21
923.78K
Avg daily vol (3M)
1.51M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-17 | Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies | Webcast |
| 2026-04-27 | Fulcrum Therapeutics First Quarter 2026 Earnings Call | Earnings call |
| 2026-03-10 | Leerink Partners Global Healthcare Conference | Conference |
| 2026-02-24 | Pociredir PIONEER Study: 20 mg Cohort Data Update | Webcast |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2025-12-07 | Virtual Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease | Event |
| 2025-07-29 | Pociredir Pioneer Study: 12 mg Cohort Data Release | Event |
Source: https://ir.fulcrumtx.com/
Key facts
CIK
1680581
CUSIP
359616109
13F (30d)
13 filings
13 filers
Visit website
Investor relations